Personalized Medicine: Neuroimaging, Genetics, Diagnosis and Improved Treatment Selection

As explained in a recent Psychiatric Times article, “Personalized medicine centers on the principle that by integrating data from a person’s genetic makeup, epigenetic modifications, clinical symptoms, biomarker changes, and environmental exposures, we can achieve greater accuracy in diagnosis, prediction of disease susceptibility, and ultimately, therapy targeted to the individual.” This session will examine the exciting progress now occurring to advance personalized medicine, common today in oncology and other areas of somatic medicine, but lacking in the field of psychiatry. Thomas Insel, MD, long-serving Director of the National Institute of Mental Health, will lead this panel with opening remarks about his work at NIMH and upcoming move to Google Life Sciences, and will moderate a discussion with the leaders of three innovative companies working in this area:

George Carpenter, CEO of MYnd Analytics
Evian Gordon, PhD, MD, Chairman and CEO of MyBrainSolutions
Jay Lombard, DO, Chief Scientific Officer and Medical Director of Genomind